Lexicon Pharmaceuticals, Inc. (LXRX) NASDAQ
2.21
+0.08(+3.76%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.21
+0.08(+3.76%)
Currency In USD
Address
2445 Technology Forest Boulevard
The Woodlands, TX 77381
United States of America (the)
Phone
281 863 3000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
103
First IPO Date
April 07, 2000
| Name | Title | Pay | Year Born |
| Michael Exton | Chief Executive Officer & Director | 1.15M | 1970 |
| Kristen L. Alexander | Vice President of Finance & Accounting | 379,807 | 1968 |
| Wendy E. McDermott | Senior Vice President of Human Resources | 580,446 | 1971 |
| Scott Coiante | Senior Vice President & Chief Financial Officer | 646,287 | 1967 |
| Brian T. Crum | Senior Vice President, General Counsel & Secretary | 687,366 | 1973 |
| Craig Granowitz | Senior Vice President & Chief Medical Officer | 789,535 | 1965 |
| Suma Gopinathan | Senior Vice President of Discovery | 0 | 1973 |
| Lisa DeFrancesco | Senior Vice President of Investor Relations & Corporate Communications | 0 | 1980 |
| Rachel Yap Martens | Senior VP of Partnerships & Corporate Strategy | 0 | 1984 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.